Akiram Therapeutics

Akiram Therapeutics is a Swedish biotechnology company based in Uppsala, founded in 2021.

The company specializes in developing targeted molecular radiotherapy, particularly radioimmunotherapy, for patients with aggressive cancers that currently lack effective treatments. Their mission is to make these therapies widely accessible and to create personalized cancer treatments with fewer side effects. The company's primary product is a radiopharmaceutical drug candidate named 177Lu-AKIR001, which has received approval to start a Phase 1 clinical trial. This therapy combines a proprietary antibody targeting the cancer marker CD44v6 with a radioactive component, delivering targeted radioactivity to cancer cells while sparing healthy tissues. Akiram focuses on treating metastatic solid tumor malignancies, including aggressive thyroid cancer, head and neck cancer, acute myeloid leukemia, lung cancer, and gynecological cancers. The company is progressing through its clinical trials, with the first cohort completed and no safety concerns reported.